Drug reference

Acebutolol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 185, 186

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Hypertension ▶BY MOUTH ▶Adult: Initially 400 mg daily for 2 weeks, alternatively initially 200 mg twice daily for 2 weeks, then increased if necessary to 400 mg twice daily; maximum 1.2 g per day Angina ▶BY MOUTH ▶Adult: Initially 400 mg daily, alternatively initially 200 mg twice daily; maximum 1.2 g per day Arrhythmias ▶BY MOUTH continued → ▶Adult: 0.4–1.2 g daily in 2–3 divided doses Severe angina ▶BY MOUTH ▶Adult: Initially 300 mg 3 times a day; maximum 1.2 g per day Cardiovascular system

PDF pages 185, 186

Safety

Interactions

→Appendix 1: beta blockers, selective

PDF page 186

Side Effects

▶Common or very common Gastrointestinal disorder ▶Frequency not known Cyanosis. hepatic disorders. lupus- like syndrome. nervous system disorder. psychosis. respiratory disorders. sexual dysfunction

PDF page 186

Breast Feeding

Acebutolol and water soluble beta- blockers are present in breast milk in greater amounts than other beta-blockers.

PDF page 186

Renal Impairment

Dose adjustments Halve dose if eGFR 25–50 mL/minute/1.73 m2; use quarter dose if eGFR less than 25 mL/minute/1.73 m2; do not administer more than once daily.

PDF page 186

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 8 ▶Sectral (Sanofi) Acebutolol (as Acebutolol hydrochloride) 400 mg Sectral 400mg tablets | 28 tablet P £18.62 DT = £18.62 Capsule CAUTIONARY AND ADVISORY LABELS 8 ▶Sectral (Sanofi) Acebutolol (as Acebutolol hydrochloride) 100 mg Sectral 100mg capsules | 84 capsule P £14.97 DT = £14.97 Acebutolol (as Acebutolol hydrochloride) 200 mg Sectral 200mg capsules | 56 capsule P £19.18 DT = £19.18 eiiii F 159

PDF page 186

Dose text by age group

Adult

Initially 400 mg daily for 2 weeks, alternatively

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

Initially 400 mg daily, alternatively initially

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

0.4–1.2 g daily in 2–3 divided doses

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

Initially 300 mg 3 times a day; maximum 1.2 g

First-line fragment. Read the complete Indications and Dose section above.

PDF page 186

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Acebutolol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 185, 186

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF pages 185, 186

Safety

Interactions

→Appendix 1: beta blockers, selective

PDF page 186

Side Effects

PDF page 186

Breast Feeding

Acebutolol and water soluble beta- blockers are present in breast milk in greater amounts than other beta-blockers.

PDF page 186

Renal Impairment

Dose adjustments Halve dose if eGFR 25–50 mL/minute/1.73 m2; use quarter dose if eGFR less than 25 mL/minute/1.73 m2; do not administer more than once daily.

PDF page 186

Dose and formulations

Medicinal Forms

PDF page 186

Dose text by age group

Adult

Initially 400 mg daily for 2 weeks, alternatively

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

Initially 400 mg daily, alternatively initially

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

0.4–1.2 g daily in 2–3 divided doses

First-line fragment. Read the complete Indications and Dose section above.

PDF page 185

Adult

Initially 300 mg 3 times a day; maximum 1.2 g

First-line fragment. Read the complete Indications and Dose section above.

PDF page 186

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.